Table 2.
Summary of CD95/CD178 polymorphisms in hematological malignancies.
| Type of malignancy | Evaluated SNPs | Number of Case/ Control | Method | Results | Ref. | |||
|---|---|---|---|---|---|---|---|---|
| CD95 | CD178 | |||||||
| rs2234767 | rs1800682 | rs763110 | ||||||
| (-1377G>A) | (-670T>C) | (-844T>C) | ||||||
| AML | United Kingdom | ✓ | ✓ | - | 454/934 | PCR-RFLP | - CD95-1377AA has twice AML development risk. - 1377A/-670A haplotype of CD95 promoter SNP had highest risk of AML development. | 18 |
| Korea | ✓ | ✓ | ✓ | 592/858 | PCR | - Not associated with AML risk in the Korean population | 19 | |
| China | - | ✓ | - | 98/2014 | Meta-Analysis | - Was not associated with AML developing. | 20 | |
| Childhood de novo AML | Multi-Ethnicity | ✓ | - | - | 440/ Not mentioned | PCR | - Reduction in CD95 enriches the expression of apoptosis resistant clones in AML blast cells. | 25 |
| Childhood ALL | China | ✓ | ✓ | - | 361/519 | PCR-RFLP | - Combination of some protection variant forms is associated with decreased risk of childhood ALL | 22 |
| ALL | Iran | ✓ | ✓ | - | 142/117 | PCR-RFLP | - –670 GG genotype is associated with liver involvement. | 23 |
| CML | India | - | ✓ | - | 386/386 | PCR-RFLP | - CD95 −670 GG and CD178 −844 TC SNPs are associated with reduced event-free survival and development of CML - CD95-670 AG associated with accelerated phase - CD178-844TC SNP associated with development of blast phase |
21 |
| ATL | Brazil | - | ✓ | - | 31/33 | PCR-RFLP | - Associated with susceptibility, clinical manifestation and survival. | 24 |
| FL | Spain | - | - | ✓ | Cohort, 126 | PCR | - The C allele in this site is associated with a better response to rituximab therapy | 26 |
AML, Acute myeloid leukemia; ALL, Acute lymphoblastic leukemia; CML, Chronic myeloid leukemia; ATL, adult T leukemia; FL, follicular lymphoma; SNP, single nucleotide polymorphism; PCR, polymerase chain reaction; PCR-RFLP, polymerase chain reaction-restriction fragment length polymorphism.